Neurocrine Biosciences executive sells shares worth $266,024

SAN DIEGO—Julie Cooke, the Chief Human Resources Officer at Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $15.4 billion biopharmaceutical company with strong financial health according to InvestingPro metrics, recently sold a substantial portion of her holdings in the company. According to a filing with the Securities and Exchange Commission, Cooke sold a total of 1,740 shares on January 31, 2025, generating approximately $266,024 in proceeds.

The shares were sold at a weighted average price of $152.89 per share, with individual transactions occurring at prices ranging from $151.85 to $153.62. The sales were executed under a pre-established Rule 10b5-1 trading plan, which was adopted by Cooke in 2022 and 2024, respectively. The transaction comes as the stock trades near its 52-week high of $157.98.

Following these transactions, Cooke continues to hold 18,202 shares directly, with an additional 16,538 shares held in the Cooke Family Trust of 2004. This indicates Cooke’s continued investment in Neurocrine Biosciences, even as she adjusts her portfolio. With the company’s impressive 25.7% revenue growth and upcoming earnings report on February 6, investors can access detailed analysis and Fair Value estimates through InvestingPro’s comprehensive research reports.

In other recent news, Neurocrine Biosciences has seen significant developments. Stifel analysts have maintained a positive outlook on Neurocrine Biosciences, following the amendment of their partnership with Takeda on the AMPA program. Neurocrine now holds full worldwide development and commercialization rights, except in Japan, for their drug osavampator/NBI-845.

In addition, Neurocrine Biosciences has sponsored a supplement in The Journal of Clinical Endocrinology & Metabolism focusing on classic congenital adrenal hyperplasia (CAH). The supplement discusses the challenges faced by individuals with classic CAH and the potential of new treatments like corticotropin-releasing factor type 1 receptor antagonists.

Oppenheimer has reiterated its Outperform rating on Neurocrine Biosciences, highlighting the recent FDA approval of Crenessity for the treatment of CAH as a pivotal event. The company has developed a strong launch plan for Crenessity, which could enhance market uptake and reimbursement processes.

Piper Sandler has expressed continued confidence in Neurocrine Biosciences, reiterating an Overweight stock rating. The firm’s analyst highlighted the promising feedback from a leading endocrinologist regarding Neurocrine’s newly launched drug Crenessity, which is used to treat adult patients with CAH. These are just a few of the recent developments at Neurocrine Biosciences.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.